This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes assessed in the review referred specifically to the Mexican American population. The outcomes assessed were:
the carrier frequency and the prevalence of CF, the detection rate of carrier status (i.e. sensitivity of the screening test), and the acceptance rates for amniocentesis and pregnancy termination.
Study designs and other criteria for inclusion in the review
The review included all published references concerning CF screening in Mexican American women. No further details of other inclusion or exclusion criteria were provided.
Sources searched to identify primary studies
The authors searched PubMed.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Approximately 5 primary studies were included in the review.
Methods of combining primary studies
Investigation of differences between primary studies
Not reported.
Results of the review
The carrier frequency of CF in Mexican individuals was 1 in 46 (22%).
The prevalence of CF in Hispanic individuals was 1 in 8,500.
The detection rate in Hispanic individuals was 57%.
The acceptance rates for amniocentesis and pregnancy termination were both 75%.
Methods used to derive estimates of effectiveness
The authors made some assumptions about the structure of the model.
Estimates of effectiveness and key assumptions
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The authors assumed the following:
female and male partners shared the same ethnic makeup and risk factors; the standard mutation panel was used for screening both women and their partners;
screening was offered in time to consider prenatal diagnosis if the couple was found to be at risk; serum samples were collected when blood was drawn for other tests in the first prenatal visit;
if screening was declined, or if the result was negative, the pregnancy resulted in a normal term delivery;
there were no false-positive results for disease or carrier status, and the false-negative rate was considered under the heading of test sensitivity;
foetal diagnosis by amniocentesis was 100% accurate.
Measure of benefits used in the economic analysis
The measure of benefit implicitly used in the analysis was the net benefit per case of CF averted. This is the difference between the cost of care saved and the direct cost of the intervention.
Direct costs
The perspective adopted in the economic analysis was that of a third-party payer. Most of the costs relevant to this perspective were included in the analysis. These comprised the costs of CF screening, amniocentesis and termination, and the costs of caring for a child with CF. Genetic counselling costs were included in the amniocentesis package. The cost data were derived from literature published between 1994 and 2002. The total costs resulting from the adoption of the screening strategy were derived through modelling.
The quantities and the costs were not analysed separately in relation to the health care cost of a child with CF. In terms of the screening programme, discounting was not relevant since the costs were incurred during less than one year. The cost of caring for a child with CF, as adopted from the literature, was inflated at an annual rate of 3% to the 2002 price. However, it was not reported whether the initial value of this cost was discounted, or the time during which this cost was incurred. The year to which the rest of the costs referred was not explicitly reported.
Statistical analysis of costs
The costs were treated deterministically. No statistical analysis of the costs was performed.
Indirect Costs
The indirect costs were not included in the analysis.
Currency
US dollars ($).
Sensitivity analysis
One-way and two-way sensitivity analyses were carried out to examine the robustness of the results. The parameters examined in the one-way analysis were the screening test cost, the test sensitivity, and the acceptance rates for amniocentesis and pregnancy termination. The two-way analyses were performed by simultaneously varying the screening test cost and the test sensitivity, and the screening test cost and the acceptance rate for pregnancy termination. The range of values used covered the total possible range (0% to 100%) for the acceptance rates. A wide range of values (from 0 to an upper realistic value) was used for the other parameters examined. Threshold analyses were also
